We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Angiotensin II Antagonism of TGF-Beta 1

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 3, 2006
Last Update Posted: August 2, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Providence Health & Services
Diabetic nephropathy is a frequent microvascular complication that occurs in approximately 40% of patients with either type 1 or type 2 diabetes. The most common cause of end-stage renal disease (ESRD) in the United States and in the developed world is diabetic nephropathy. Currently, more than half the United States ESRD population has diabetes. More effective therapies to prevent and treat diabetic nephropathy are urgently needed. One way to increase therapeutic effectiveness is to refine treatment targets based on improved understanding of how treatments modulate disease processes. The purpose of this study is to determine whether a treatment for diabetic nephropathy, the angiotensin receptor blocker candesartan, modifies mediators of kidney injury independent of blood pressure and the relationships to drug dose.

Condition Intervention
Diabetic Nephropathy Hypertension Drug: Candesartan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study

Resource links provided by NLM:

Further study details as provided by Providence Health & Services:

Primary Outcome Measures:
  • Blood pressure
  • Urinary TGF-Beta 1
  • Serum angiotensin II
  • Urinary albumin
  • Urinary carboxymethyllysine

Estimated Enrollment: 36
Study Start Date: August 2002
Estimated Study Completion Date: September 2004
  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Type 2 diabetes
  • Nephropathy (proteinuria >500 mg/day)
  • Chronic Hypertension (as determined by current antihypertensive therapy and/or an average of diastolic blood pressure greater than 90 mmHg or greater or systolic blood pressure of 140 mmHg confirmed on at least two subsequent visits over one week or more).

Exclusion Criteria:

  • Conditions associated with elevated TGF-Beta (e.g. rheumatoid arthritis, cancer, etc.).
  • Conditions associated with alterations in serum levels of PIP and/or CITP (liver cirrhosis, osteoporosis, hyperthyroidism, multiple myeloma, osteolytic metastases, and systemic glucocorticoid treatment
  • History of Stage III hypertension (diastolic BP > 110 mmHg or systolic BP > 180 mmHg) or a history of hypertensive urgency or emergency.
  • NYHA Class III or IV heart failure
  • Calculated creatinine clearance of less than 30 ml/min or serum creatinine > 3 mg/dL
  • HbA1c > 10%
  • Patients unable to be withdrawn for 2 weeks from AT-II antagonist or ACE- inhibitor therapy
  • Blood Pressure <140/90 is unachievable in the absence of an AT-II antagonist or ACE-inhibitor
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00320970

United States, Washington
Providence Medical Research Center
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Providence Health & Services
Principal Investigator: Katherine R. Tuttle, MD,FASN,FACP Providence Medical Research Center
  More Information

ClinicalTrials.gov Identifier: NCT00320970     History of Changes
Other Study ID Numbers: HI831
First Submitted: April 28, 2006
First Posted: May 3, 2006
Last Update Posted: August 2, 2007
Last Verified: March 2006

Keywords provided by Providence Health & Services:
TGF-Beta 1
Angiotensin II
Advanced glycation end products

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Candesartan cilexetil
Angiotensin II
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors